Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open Label, Randomized, Parallel-group, Single Center Study to Investigate Pharmacokinetics and Pharmacodynamics (Intragastric pH) of Linaprazan Glurate/Linaprazan After Single and 14 Days'Repeated Oral Administration of Linaprazan Glurate to Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Open Label, Randomized, Parallel-group, Single Center Study to Investigate Pharmacokinetics and Pharmacodynamics (Intragastric pH) of Linaprazan Glurate/Linaprazan After Single and 14 Days'Repeated Oral Administration of Linaprazan Glurate to Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linaprazan-glurate (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Cinclus Pharma

Most Recent Events

  • 06 May 2025 According to a Cinclus Pharma media release, the positive data of this study was presented at the international conference Digestive Disease Week held in San Diego
  • 24 Sep 2024 According to a Cinclus Pharma media release, the results of this study, showing rapid and effective acid inhibition in 90 min after first dosing, will be presented at United European Gastroenterology Week (UEG) 12 - 15 October 2024. The abstract titled- "Pharmacokinetics and pharmacodynamics of Linaprazan glurate after multiple oral doses up to 14 days in healthy subjects", will be presented on Sunday, October 13, 16:18 - 16:30.
  • 29 Aug 2024 According to a Cinclus Pharma media release, company's Phase I study (PK/PD) were completed during the period (Apr - Jun 2024). This study has been submitted for a presentation at UEGW, a scientific congress within the gastroenterology area, later this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top